{"id":2439,"date":"2026-10-30T17:28:23","date_gmt":"2026-10-30T17:28:23","guid":{"rendered":"https:\/\/chatscopeai.com\/news\/hhs-eases-enforcement-on-pharmacy-compounding-of-six-peptides\/"},"modified":"2026-10-30T17:28:25","modified_gmt":"2026-10-30T17:28:25","slug":"hhs-eases-enforcement-on-pharmacy-compounding-of-six-peptides","status":"publish","type":"post","link":"https:\/\/chatscopeai.com\/news\/hhs-eases-enforcement-on-pharmacy-compounding-of-six-peptides\/","title":{"rendered":"HHS Eases Enforcement on Pharmacy Compounding of Six Peptides"},"content":{"rendered":"\n<p class=\"wp-block-paragraph hsn-lede\">HHS will not act against pharmacies compounding six peptides that meet 10 conditions. Comments are due two weeks after Oct. 30, 2026.<\/p>\n<p class=\"wp-block-paragraph\"><strong>The US Department of Health and Human Services (HHS) will not take action against pharmacies that compound six peptides under strict conditions. Comments on the policy are open for 2 weeks after its Oct. 30, 2026 publication.<\/strong><\/p>\n<p class=\"wp-block-paragraph\">HHS published a notice in the Federal Register announcing an interim enforcement policy for six peptide ingredients used in compounded drugs<sup class=\"hsn-cite\"><a href=\"#hsn-ref-1\" id=\"hsn-cite-1\">1<\/a><\/sup>. It covers state-licensed pharmacies, federal facilities and licensed physicians that mix these drugs for individual patients<sup class=\"hsn-cite\"><a href=\"#hsn-ref-2\" id=\"hsn-cite-2\">2<\/a><\/sup>. The policy applies while the Food and Drug Administration (FDA) builds the official list of allowed ingredients through formal rulemaking<sup class=\"hsn-cite\"><a href=\"#hsn-ref-1\">1<\/a><\/sup>.<\/p>\n<div class=\"hsn-table\">\n<div class=\"pcrstb-wrap\"><table>\n<thead><tr><th>At a glance<\/th><th>Details<\/th><\/tr><\/thead>\n<tbody>\n<tr><td>What was published<\/td><td>Interim enforcement policy, announced as a draft notice<\/td><\/tr>\n<tr><td>Published on<\/td><td>30 October 2026<\/td><\/tr>\n<tr><td>Who can comment \/ Who must comply<\/td><td>State-licensed pharmacies, federal facilities and licensed physicians that compound drugs<\/td><\/tr>\n<tr><td>Feedback deadline \/ Effective date<\/td><td>Comments due 2 weeks after 30 October 2026<\/td><\/tr>\n<tr><td>Final rules \/ Next milestone<\/td><td>FDA rulemaking on the list of allowed ingredients<\/td><\/tr>\n<\/tbody>\n<\/table><\/div>\n<\/div>\n<h2 class=\"wp-block-heading\">What is the peptide policy, and why does it matter?<\/h2>\n<p class=\"wp-block-paragraph\">Compounding means a licensed pharmacist or physician mixes or alters ingredients to make a medicine for one patient<sup class=\"hsn-cite\"><a href=\"#hsn-ref-2\">2<\/a><\/sup>. Compounded drugs are not FDA-approved, so the FDA does not review their safety, effectiveness or quality before sale<sup class=\"hsn-cite\"><a href=\"#hsn-ref-2\">2<\/a><\/sup>. Under federal law, pharmacies may only use bulk ingredients that meet set standards, are part of approved drugs, or appear on an official list<sup class=\"hsn-cite\"><a href=\"#hsn-ref-2\">2<\/a><\/sup>.<\/p>\n<p class=\"wp-block-paragraph\">The six peptides covered here meet none of those tests yet. HHS says the policy will discourage the <strong>widespread use of research-use-only peptides<\/strong> supplied by foreign manufacturers that pose a safety risk to US patients<sup class=\"hsn-cite\"><a href=\"#hsn-ref-2\">2<\/a><\/sup>. It calls the policy a more controlled alternative that advances patient choice while protecting safety<sup class=\"hsn-cite\"><a href=\"#hsn-ref-2\">2<\/a><\/sup>.<\/p>\n<h2 class=\"wp-block-heading\">Which six peptides are covered?<\/h2>\n<p class=\"wp-block-paragraph\">The policy lists the peptides in its Appendix A<sup class=\"hsn-cite\"><a href=\"#hsn-ref-2\">2<\/a><\/sup>. Each one may be used only in certain forms, set out in Appendix B<sup class=\"hsn-cite\"><a href=\"#hsn-ref-2\">2<\/a><\/sup>.<\/p>\n<div class=\"hsn-table\">\n<div class=\"pcrstb-wrap\"><table>\n<thead><tr><th>Peptide<\/th><th>Allowed forms<\/th><\/tr><\/thead>\n<tbody>\n<tr><td>BPC-157 acetate<\/td><td>Injection under the skin or into muscle, oral and topical<\/td><\/tr>\n<tr><td>TB-500 acetate<\/td><td>Injection under the skin or into muscle<\/td><\/tr>\n<tr><td>Epitalon acetate<\/td><td>Injection under the skin or into muscle, in intermittent courses<\/td><\/tr>\n<tr><td>Semax free base<\/td><td>Nasal use<\/td><\/tr>\n<tr><td>KPV acetate<\/td><td>Topical and oral<\/td><\/tr>\n<tr><td>MOTS-c acetate<\/td><td>Injection under the skin or into muscle<\/td><\/tr>\n<\/tbody>\n<\/table><\/div>\n<\/div>\n<p class=\"wp-block-paragraph\">All six were on the FDA&#8217;s &quot;Category 2&quot; list from September 2023 until <strong>April 22, 2026<\/strong><sup class=\"hsn-cite\"><a href=\"#hsn-ref-2\">2<\/a><\/sup>. FDA&#8217;s drug review center recommended against listing each of them. The Pharmacy Compounding Advisory Committee, an expert panel that advises FDA, voted in favor<sup class=\"hsn-cite\"><a href=\"#hsn-ref-2\">2<\/a><\/sup>.<\/p>\n<h2 class=\"wp-block-heading\">What pharmacies must do to qualify<\/h2>\n<p class=\"wp-block-paragraph\">HHS will hold back enforcement only when <strong>all 10 conditions<\/strong> are met<sup class=\"hsn-cite\"><a href=\"#hsn-ref-2\">2<\/a><\/sup>. The main ones are:<\/p>\n<ul>\n<li>The ingredient must come from a facility registered with the FDA, with a valid certificate of analysis<sup class=\"hsn-cite\"><a href=\"#hsn-ref-2\">2<\/a><\/sup>.<\/li>\n<li>The original manufacturer must be FDA-registered and follow good manufacturing rules, with its location listed on the certificate<sup class=\"hsn-cite\"><a href=\"#hsn-ref-2\">2<\/a><\/sup>.<\/li>\n<li>Each compounded product may contain <strong>only one active ingredient<\/strong> from the list<sup class=\"hsn-cite\"><a href=\"#hsn-ref-2\">2<\/a><\/sup>.<\/li>\n<li>The only delivery device allowed is an FDA-cleared syringe<sup class=\"hsn-cite\"><a href=\"#hsn-ref-2\">2<\/a><\/sup>.<\/li>\n<li>Labels must state: &quot;This is a compounded drug product. Not for resale.&quot;<sup class=\"hsn-cite\"><a href=\"#hsn-ref-2\">2<\/a><\/sup><\/li>\n<li>Each drug still needs a valid prescription for a specific patient<sup class=\"hsn-cite\"><a href=\"#hsn-ref-2\">2<\/a><\/sup>.<\/li>\n<\/ul>\n<p class=\"wp-block-paragraph\">For oral products, the pharmacy must keep records showing the patient&#8217;s body absorbs enough of the peptide<sup class=\"hsn-cite\"><a href=\"#hsn-ref-2\">2<\/a><\/sup>. HHS says oral absorption of peptides is inherently difficult<sup class=\"hsn-cite\"><a href=\"#hsn-ref-2\">2<\/a><\/sup>.<\/p>\n<h2 class=\"wp-block-heading\">Testing and reporting duties<\/h2>\n<p class=\"wp-block-paragraph\">The certificate of analysis must show test results for identity, purity and strength<sup class=\"hsn-cite\"><a href=\"#hsn-ref-2\">2<\/a><\/sup>. It must also cover harmful contaminants such as endotoxins, heavy metals and microbes<sup class=\"hsn-cite\"><a href=\"#hsn-ref-2\">2<\/a><\/sup>. Appendix B sets out a testing standard listing methods for each quality check<sup class=\"hsn-cite\"><a href=\"#hsn-ref-2\">2<\/a><\/sup>.<\/p>\n<p class=\"wp-block-paragraph\">Pharmacies must report <strong>serious adverse events<\/strong> to MedWatch, the FDA&#8217;s safety reporting program<sup class=\"hsn-cite\"><a href=\"#hsn-ref-2\">2<\/a><\/sup>. They must report these whether or not the drug seems to be the cause. Product quality problems, such as contamination, must also be reported, and the states involved must be informed<sup class=\"hsn-cite\"><a href=\"#hsn-ref-2\">2<\/a><\/sup>.<\/p>\n<div class=\"hsn-table\">\n<div class=\"pcrstb-wrap\"><table>\n<thead><tr><th>Reporting item<\/th><th>What pharmacies must include<\/th><\/tr><\/thead>\n<tbody>\n<tr><td>Active ingredient<\/td><td>Name and strength per unit<\/td><\/tr>\n<tr><td>Original manufacturer<\/td><td>Name and unique facility identifier<\/td><\/tr>\n<tr><td>Product form<\/td><td>Dosage form and route of use<\/td><\/tr>\n<\/tbody>\n<\/table><\/div>\n<\/div>\n<h2 class=\"wp-block-heading\">How long the policy lasts<\/h2>\n<p class=\"wp-block-paragraph\">The policy runs until each peptide is addressed in a final rule, either added to or left off the official list<sup class=\"hsn-cite\"><a href=\"#hsn-ref-2\">2<\/a><\/sup>. Future FDA rules may propose adding some or all six peptides, based on the evidence<sup class=\"hsn-cite\"><a href=\"#hsn-ref-1\">1<\/a><\/sup>. HHS may revisit the policy if a <strong>safety signal or quality issue<\/strong> arises<sup class=\"hsn-cite\"><a href=\"#hsn-ref-1\">1<\/a><\/sup>.<\/p>\n<p class=\"wp-block-paragraph\">The notice says the policy creates no rights and does not bind HHS or the public<sup class=\"hsn-cite\"><a href=\"#hsn-ref-1\">1<\/a><\/sup>. Comments go to Docket No. HHS-OASH-2026-0496 on regulations.gov<sup class=\"hsn-cite\"><a href=\"#hsn-ref-1\">1<\/a><\/sup>.<\/p>\n<h2 class=\"wp-block-heading\">Key terms in plain words<\/h2>\n<div class=\"hsn-table\">\n<div class=\"pcrstb-wrap\"><table>\n<thead><tr><th>Term<\/th><th>Meaning<\/th><\/tr><\/thead>\n<tbody>\n<tr><td>Compounding<\/td><td>Mixing or altering drug ingredients to make a medicine for one patient<\/td><\/tr>\n<tr><td>Enforcement discretion<\/td><td>A choice by the government not to take legal action in set cases<\/td><\/tr>\n<tr><td>503A<\/td><td>The section of US drug law covering pharmacy compounding<\/td><\/tr>\n<tr><td>Bulk drug substance<\/td><td>The raw active ingredient used to make a medicine<\/td><\/tr>\n<tr><td>Certificate of analysis<\/td><td>A lab report confirming an ingredient&#8217;s identity, purity and testing<\/td><\/tr>\n<tr><td>MedWatch<\/td><td>The FDA&#8217;s program for reporting drug safety problems<\/td><\/tr>\n<\/tbody>\n<\/table><\/div>\n<\/div>\n<p class=\"wp-block-paragraph\">Public comments on the policy are due 2 weeks after its Oct. 30, 2026 publication in the Federal Register<sup class=\"hsn-cite\"><a href=\"#hsn-ref-1\">1<\/a><\/sup>.<\/p>\n<h2 class=\"wp-block-heading hsn-refs-title\">Sources<\/h2>\n<ol class=\"hsn-refs\">\n<li id=\"hsn-ref-1\"><a class=\"hsn-refs__back\" href=\"#hsn-cite-1\" aria-label=\"Back to reference 1 in the text\">\u21a9<\/a> <a href=\"https:\/\/www.federalregister.gov\/documents\/2026\/10\/30\/2026-22192\/enforcement-discretion-policy-regarding-503a-compounding-using-certain-peptide-bulk-drug-substances\" rel=\"noopener\" target=\"_blank\">Federal Register\n       :: \n      Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances<\/a> <span class=\"hsn-refs__url\">https:\/\/www.federalregister.gov\/documents\/2026\/10\/30\/2026-22192\/enforcement-discretion-policy-regarding-503a-compounding-using-certain-peptide-bulk-drug-substances<\/span><\/li>\n<li id=\"hsn-ref-2\"><a class=\"hsn-refs__back\" href=\"#hsn-cite-2\" aria-label=\"Back to reference 2 in the text\">\u21a9<\/a> <a href=\"https:\/\/www.hhs.gov\/sites\/default\/files\/hhs-503a-peptide-enforcement-discretion-policy-appendix-b.pdf\" rel=\"noopener\" target=\"_blank\">hhs-503a-peptide-enforcement-discretion-policy-appendix-b.pdf<\/a> <span class=\"hsn-refs__url\">https:\/\/www.hhs.gov\/sites\/default\/files\/hhs-503a-peptide-enforcement-discretion-policy-appendix-b.pdf<\/span><\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"<p>HHS will not act against pharmacies compounding six peptides that meet 10 conditions. Comments are due two weeks after Oct. 30, 2026.<\/p>\n","protected":false},"author":1,"featured_media":2437,"comment_status":"closed","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"_lmt_disableupdate":"","_lmt_disable":"","_regnews_id":"36024","_hsn_citations":"[{\"n\":1,\"url\":\"https:\/\/www.federalregister.gov\/documents\/2026\/10\/30\/2026-22192\/enforcement-discretion-policy-regarding-503a-compounding-using-certain-peptide-bulk-drug-substances\",\"label\":\"Federal Register\\n       :: \\n      Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances\"},{\"n\":2,\"url\":\"https:\/\/www.hhs.gov\/sites\/default\/files\/hhs-503a-peptide-enforcement-discretion-policy-appendix-b.pdf\",\"label\":\"hhs-503a-peptide-enforcement-discretion-policy-appendix-b.pdf\"}]","_hsn_no_sources":"","_hsn_content_hash":"adecfb1ec0d83a88af617fc552d63d29afcb4718:8ac1e2497bd32d492bad178319be05d7571c75be","_yoast_wpseo_focuskw":"pharmaceuticals","footnotes":""},"categories":[58,40],"tags":[50],"class_list":["post-2439","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-americas","category-pharma-medical","tag-united-states-of-america"],"_links":{"self":[{"href":"https:\/\/chatscopeai.com\/news\/wp-json\/wp\/v2\/posts\/2439","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/chatscopeai.com\/news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/chatscopeai.com\/news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/chatscopeai.com\/news\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/chatscopeai.com\/news\/wp-json\/wp\/v2\/comments?post=2439"}],"version-history":[{"count":1,"href":"https:\/\/chatscopeai.com\/news\/wp-json\/wp\/v2\/posts\/2439\/revisions"}],"predecessor-version":[{"id":2441,"href":"https:\/\/chatscopeai.com\/news\/wp-json\/wp\/v2\/posts\/2439\/revisions\/2441"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/chatscopeai.com\/news\/wp-json\/wp\/v2\/media\/2437"}],"wp:attachment":[{"href":"https:\/\/chatscopeai.com\/news\/wp-json\/wp\/v2\/media?parent=2439"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/chatscopeai.com\/news\/wp-json\/wp\/v2\/categories?post=2439"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/chatscopeai.com\/news\/wp-json\/wp\/v2\/tags?post=2439"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}